Home / Information / Lorlatinib
Lorlatinib
Lorlatinib is a 3rd generation TKI developed by Pfizer. The recommended dose is 100mg taken daily.
Documents
Name
Summary of Contents
Action
Managing Lorlatinib Together
NEW
An overview and practical guide for patients by ALK-positive patients and medical experts.
Increased cardiovascular risk with Lorlatinib
NEW
Patients receiving lorlatinib have an increased risk of developing cardiovascular diseases, particularly heart failure and stroke.
Management of Side Effects
A guide for health care professionals on the management of adverse effects arising from Lorlatinib.
Use of Lorlatinib with Paxlovid
Paxlovid is used to treat early Covid-19 infections. Here is Pfizer's statement about using it with Lorlatinib.
Crown Study 5-year Outcomes
This report contains information on the effectiveness of Lorlatinib for 1st line use.
Lorlatinib What to Expect (Pfizer)
A booklet from Pfizer on the side effects that patients may experience.
Weight Gain
Patients with weight gain of over 5% within 6 months developed significantly higher maximum gain
Lorlatinib - An Oncologist's Opinion
A discussion with Dr Camidge, a leading USA ALK+ expert.